Selection of appropriate end-points (pCR vs 2yDFS) for tailoring treatments with prediction models in locally advanced rectal cancer
- 1 March 2015
- journal article
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 114 (3) , 302-309
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Delivering affordable cancer care in high-income countriesThe Lancet Oncology, 2011
- Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: Data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803European Journal of Cancer, 2011
- Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient dataThe Lancet Oncology, 2010
- The use of FDG-PET/CT and diffusion-weighted magnetic resonance imaging for response prediction before, during and after preoperative chemoradiotherapy for rectal cancerActa Oncologica, 2010
- Prognostic Value of Pathologic Complete Response After Neoadjuvant Therapy in Locally Advanced Rectal Cancer: Long-Term Analysis of 566 ypCR PatientsInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2008
- Preoperative Radiotherapy With or Without Concurrent Fluorouracil and Leucovorin in T3-4 Rectal Cancers: Results of FFCD 9203Journal of Clinical Oncology, 2006
- Chemotherapy with Preoperative Radiotherapy in Rectal CancerNew England Journal of Medicine, 2006
- Primary radical external beam radiotherapy of rectal adenocarcinoma: Long term outcome of 271 patientsRadiotherapy and Oncology, 2005
- Preoperative versus Postoperative Chemoradiotherapy for Rectal CancerNew England Journal of Medicine, 2004
- Improved methodology for analyzing local and distant recurrence.Journal of Clinical Oncology, 1990